Current Price
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. The company is headqua...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
Earnings estimates are not available for this company.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TTRADESTATI... | TRAD | $147.69M | 126.12 | 1.27 | — | — | — | — |
| 2. | TTRADESTATI... | TRAD | $147.69M | 126.12 | 1.27 | — | — | — | — |
| 3. | AAperture A... | APUR | $148.37M | — | — | — | — | — | — |
| 4. | NSouthern C... | NCO | $146.85M | — | — | — | — | — | — |
| 5. | XXFLH Capit... | XFLH | $146.33M | — | — | — | — | — | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Sep 21 | Dec 21 | Mar 22 | Jun 22 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - |
| 0 | 0 | 0.49 | 0.52 | |
EBIT | 0 | 0 | -0.49 | -0.52 |
OPM % | - | - | - | - |
Non-Operating Income | 0 | 0 | -0.01 | -0.02 |
PBT | 0 | 0 | -0.5 | -0.54 |
Income Tax | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - |
Net Income | 0 | 0 | -0.5 | -0.54 |
NPM % | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
Revenue | 0 | 0 | 0 |
COGS | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 |
Gross Profit % | - | - | - |
| 0 | 1.67 | 0.9 | |
EBIT | 0 | -1.67 | -0.9 |
OPM % | - | - | - |
Non-Operating Income | 0 | -0.03 | -0.05 |
PBT | 0 | -1.7 | -0.96 |
Income Tax | 0 | 0 | 0 |
Tax Rate % | - | - | - |
Net Income | 0 | -1.7 | -0.96 |
NPM % | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| 0 | 0.02 | 0.04 | |
| 0 | 0 | 0 | |
| 0 | 0 | 0 | |
| 1.3 | 0.04 | 0.11 | |
| 0 | 0 | 0 | |
Total Assets | 0 | 0.06 | 0.15 |
| 0 | 0 | 0 | |
| -2.29 | -1.07 | -0.74 | |
| 0 | 0.8 | 0.2 | |
| 0.66 | 0 | 0.5 | |
| 0 | 0.33 | 0.19 | |
Total Liabilities | 0 | 0.06 | 0.15 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| -1.62 | -2.07 | -0.28 | |
| 0 | 0 | 0 | |
| 2.92 | 0.8 | 0.3 | |
Net CFNet Cash Flow | 1.29 | -1.27 | 0.02 |
FCFFree Cash Flow | -1.62 | -2.07 | -0.28 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2019 | Dec 2020 | Dec 2021 |
|---|---|---|---|
| - | - | 105.6% | |
| - | -0.56 | -0.27 | |
| 1.95 | 0.12 | 0.22 | |
| - | - | 0.00 | |
Cash Conversion | - | 1.22 | 0.29 |
Payout Ratio | - | - | - |
| - | - | - | |
| - | - | - | |
| - | - | - | |
| 1.00 | 1.00 | 5.00 | |
| - | - | - | |
| - | - | - | |
| - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Alpex Acquisition Corp - Class A, from SEC filings
Shares sold short · updated twice a month
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 30 Oct 2026 | 733 | -99.1% | 1.00 | |
| 15 Oct 2026 | 80,484 | +62290.7% | 2.10 | |
| 30 Sep 2026 | 129 | -79.1% | 1.00 | |
| 15 Sep 2026 | 616 | -28.3% | 1.00 | |
| 31 Aug 2026 | 859 | +813.8% | 1.00 | |
| 14 Aug 2026 | 94 | +118.6% | 1.00 | |
| 31 Jul 2026 | 43 | -99.9% | 1.00 | |
| 15 Jul 2026 | 32,063 | 1.00 |
FINRA consolidated short interest, reported twice a month for every US listing.
Alpex Acquisition Corp - Class A's SEC filings and earnings call transcripts
What recent news says about Alpex Acquisition Corp - Class A, scored for sentiment.